Total Payments
$2.7M
2024 Payments
$386,401
Companies
57
Transactions
2,655
Medicare Patients
6,906
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$1.3M (48.6%)
Consulting$1.0M (37.6%)
Travel$236,748 (8.7%)
Food & Beverage$91,425 (3.4%)
Research$40,991 (1.5%)
Gifts$5,746 (0.2%)
Education$1,026 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.0M | 496 | 37.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $822,213 | 364 | 30.4% |
| Honoraria | $245,515 | 64 | 9.1% |
| Travel and Lodging | $236,748 | 472 | 8.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $133,625 | 55 | 4.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $105,740 | 35 | 3.9% |
| Food and Beverage | $91,425 | 1,146 | 3.4% |
| Unspecified | $40,991 | 10 | 1.5% |
| Long term medical supply or device loan | $8,006 | 1 | 0.3% |
| Gift | $5,746 | 6 | 0.2% |
| Education | $1,026 | 6 | 0.0% |
Payments by Type
General
$2.7M
2,645 transactions
Research
$40,991
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $508,985 | 640 | $0 (2022) |
| Ellex, Inc | $314,721 | 192 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $226,349 | 214 | $0 (2024) |
| EllexiScience | $182,857 | 17 | $0 (2019) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $177,940 | 241 | $0 (2021) |
| Glaukos Corporation | $164,143 | 129 | $0 (2024) |
| ABBVIE INC. | $159,990 | 151 | $0 (2024) |
| Alcon Vision LLC | $142,209 | 124 | $0 (2024) |
| Reichert, Inc. | $95,421 | 51 | $0 (2024) |
| Carl Zeiss Meditec, Inc. | $90,936 | 97 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $386,401 | 322 | Bausch & Lomb Americas Inc. ($100,638) |
| 2023 | $357,857 | 305 | Bausch & Lomb Americas Inc. ($92,582) |
| 2022 | $382,898 | 366 | ABBVIE INC. ($81,841) |
| 2021 | $332,153 | 363 | Allergan, Inc. ($116,230) |
| 2020 | $274,878 | 279 | Allergan, Inc. ($119,046) |
| 2019 | $329,832 | 404 | Allergan Inc. ($83,661) |
| 2018 | $371,384 | 380 | Ellex, Inc ($86,444) |
| 2017 | $272,826 | 236 | EllexiScience ($94,701) |
All Payment Transactions
2,655 individual payment records from CMS Open Payments — Page 1 of 107
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Ellex, Inc | TANGO OPTIMO (Device) | Food and Beverage | Cash or cash equivalent | $18,000.00 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Carl Zeiss Meditec, Inc. | CIRRUS HD-OCT (Device), Retina Workplace, FORUM | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,240.00 | General |
| Category: Optical Tomography | ||||||
| 12/04/2024 | Glaukos Corporation | iDose (Device) | Consulting Fee | Cash or cash equivalent | $6,890.00 | General |
| Category: Glaucoma | ||||||
| 12/04/2024 | NEW WORLD MEDICAL,INC. | Kahook Dual Blade (Device), Clearpath, Ahmed Glaucoma Valve | Food and Beverage | In-kind items and services | $11.46 | General |
| Category: Ophthalmology | ||||||
| 12/02/2024 | Rayner Intraocular Lenses Limited | Omidria (Drug) | — | Cash or cash equivalent | $3,200.00 | Research |
| Study: Omidria Dropless RCT • Category: Ophthalmology | ||||||
| 11/26/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,062.50 | General |
| Category: Ophthalmology | ||||||
| 11/21/2024 | Alcon Vision LLC | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Ophthalmology | ||||||
| 11/21/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $25.32 | General |
| Category: EYE CARE | ||||||
| 11/21/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: EYE CARE | ||||||
| 11/20/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,950.00 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 11/20/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/19/2024 | Bausch & Lomb Americas Inc. | VYZULTA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,800.00 | General |
| Category: Ophthalmology | ||||||
| 11/18/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/15/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Dry eyes | ||||||
| 11/07/2024 | Alcon Vision LLC | HYDRUS Microstent (Device) | Consulting Fee | Cash or cash equivalent | $15,500.00 | General |
| Category: Ophthalmology | ||||||
| 11/07/2024 | Alcon Vision LLC | HYDRUS Microstent (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Ophthalmology | ||||||
| 11/07/2024 | Carl Zeiss Meditec, Inc. | CIRRUS HD-OCT (Device), FORUM, FORUM Glaucoma Workplace | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| Category: Optical Tomographer | ||||||
| 11/07/2024 | Alcon Research LLC | — | Consulting Fee | Cash or cash equivalent | $2,380.00 | General |
| 11/07/2024 | Carl Zeiss Meditec, Inc. | CIRRUS HD-OCT (Device), CIRRUS 5000 with AngioPlex, CLARUS | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,215.00 | General |
| Category: Optical Tomography | ||||||
| 11/07/2024 | Alcon Vision LLC | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Ophthalmology | ||||||
| 11/06/2024 | Glaukos Corporation | iDose (Device) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: Glaucoma | ||||||
| 11/06/2024 | Reichert, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 11/06/2024 | Glaukos Corporation | iDose (Device) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: Glaucoma | ||||||
| 11/05/2024 | Harrow Eye, LLC | VEVYE (Drug) | Food and Beverage | In-kind items and services | $34.72 | General |
| Category: OPTOMETRY | ||||||
| 11/01/2024 | Alcon Vision LLC | — | Travel and Lodging | In-kind items and services | $363.95 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Omidria Dropless RCT | Rayner Intraocular Lenses Limited | $10,000 | 2 |
| An Observational Multicenter Clinical Study to Assess the Long-term Safety and Effectiveness of the OMNI Surgical System in Combination with Cataract Surgery in Eyes with Open Angle Glaucoma (GEMINI 2.0) | Sight Sciences, Inc. | $7,897 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $7,275 | 1 |
| Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% | Glaukos Corporation | $5,991 | 2 |
| An observational multicenter clinical study to assess the long-term safety and effectiveness of the OMNI Surgical System in combination with cataract surgery in eyes with open angle glaucoma (GEMINI 2.0) | Sight Sciences, Inc. | $4,968 | 1 |
| A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery | Glaukos Corporation | $4,850 | 1 |
| XEN-45 GEL STENT VERSUS TRABECULECTOMY IN GLAUCOMA: GOLD-STANDARD PATHWAY STUDY (GPS) | Allergan, Inc. | $10.13 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 1,853 | 2,562 | $1.8M | $272,380 |
| 2022 | 26 | 1,523 | 2,116 | $1.4M | $221,338 |
| 2021 | 34 | 1,937 | 2,986 | $2.0M | $387,005 |
| 2020 | 24 | 1,593 | 2,277 | $1.5M | $273,469 |
Total Patients
6,906
Total Services
9,941
Medicare Billing
$1.2M
Procedure Codes
116
All Medicare Procedures & Services
116 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2023 | 80 | 142 | $552,824 | $52,756 | 9.5% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2023 | 67 | 107 | $116,914 | $26,269 | 22.5% |
| 67031 | Release of scar tissue between lens and retina using a laser | Office | 2023 | 45 | 91 | $150,743 | $25,076 | 16.6% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Office | 2023 | 26 | 45 | $175,188 | $17,141 | 9.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 161 | 247 | $30,100 | $14,491 | 48.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 150 | 161 | $25,256 | $13,689 | 54.2% |
| 66183 | Insertion of eye fluid drainage device | Facility | 2023 | 17 | 18 | $55,802 | $13,593 | 24.4% |
| 67904 | Repair of tendon of upper eyelid | Office | 2023 | 14 | 14 | $89,125 | $11,456 | 12.9% |
| 65855 | Laser repair to improve eye fluid flow | Office | 2023 | 39 | 62 | $122,336 | $10,986 | 9.0% |
| 65820 | Incision to improve eye fluid flow | Facility | 2023 | 12 | 16 | $32,736 | $10,096 | 30.8% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 159 | 174 | $17,570 | $10,047 | 57.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 82 | 82 | $18,605 | $9,021 | 48.5% |
| 66991 | Extracapsular removal of cataract with insertion of artificial lens and insertion of drainage device in front chamber of eye | Facility | 2023 | 11 | 16 | $95,584 | $7,164 | 7.5% |
| 64708 | Release of arm or leg nerve | Facility | 2023 | 20 | 34 | $26,282 | $6,930 | 26.4% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 124 | 234 | $46,314 | $6,487 | 14.0% |
| 64727 | Release of nerve using operating microscope | Office | 2023 | 27 | 47 | $24,205 | $6,316 | 26.1% |
| 66174 | Dilation of fluid outflow drainage within eye | Facility | 2023 | 11 | 14 | $38,218 | $5,220 | 13.7% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 112 | 141 | $17,221 | $5,073 | 29.5% |
| 92134 | Imaging of retina | Office | 2023 | 73 | 115 | $21,520 | $3,212 | 14.9% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 130 | 158 | $16,274 | $3,042 | 18.7% |
| 92285 | Photography of content of eyes | Office | 2023 | 158 | 177 | $15,937 | $2,742 | 17.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 38 | 38 | $6,037 | $2,454 | 40.7% |
| 68841 | Insertion of drug delivery implant into tear duct of eye | Facility | 2023 | 95 | 167 | $28,725 | $2,069 | 7.2% |
| V2632 | Posterior chamber intraocular lens | Office | 2023 | 11 | 18 | $13,911 | $1,919 | 13.8% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Office | 2023 | 27 | 47 | $7,282 | $1,805 | 24.8% |
About Inder Singh
Inder Singh is a Ophthalmology healthcare provider based in Racine, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063430023.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Inder Singh has received a total of $2.7M in payments from pharmaceutical and medical device companies, with $386,401 received in 2024. These payments were reported across 2,655 transactions from 57 companies. The most common payment nature is "Consulting Fee" ($1.0M).
As a Medicare-enrolled provider, Singh has provided services to 6,906 Medicare beneficiaries, totaling 9,941 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 116 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Racine, WI
- Active Since 07/18/2006
- Last Updated 07/08/2007
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1063430023
Products in Payments
- DURYSTA (Drug) $252,429
- Tango-R SLT/YAG Combination Laser with Reflex Technology (Device) $236,675
- VYZULTA (Drug) $153,716
- LUMIGAN (Drug) $151,685
- HYDRUS Microstent (Device) $104,221
- XEN (Device) $60,927
- OMNI(R) SURGICAL SYSTEM (US) (Device) $60,780
- DEXTENZA (Drug) $52,429
- XEN GLAUCOMA TREATMENT SYSTEM (Device) $51,197
- STELLARIS ELITE (Device) $47,449
- UltraQ-R Nd: YAG Laser with Reflex Technology (Device) $46,955
- iDose (Device) $46,472
- VUITY (Drug) $43,068
- XIIDRA (Drug) $38,827
- TYRVAYA (Drug) $36,558
- LOTEMAX SM (Drug) $34,413
- Rocklatan (Drug) $34,277
- rocklatan (Drug) $32,176
- MIEBO (Drug) $30,408
- Rhopressa (Drug) $29,551
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.